Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 19,400 shares, an increase of 22.8% from the August 31st total of 15,800 shares. Approximately 3.4% of the company’s shares are sold short. Based on an average daily volume of 25,600 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $0.20 price target on shares of Cadrenal Therapeutics in a research report on Thursday, June 6th.

Cadrenal Therapeutics Stock Performance

Shares of CVKD stock traded up $0.19 on Monday, hitting $14.69. The company’s stock had a trading volume of 14,424 shares, compared to its average volume of 22,376. The company has a market capitalization of $235.16 million, a PE ratio of -47.39 and a beta of 1.74. Cadrenal Therapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $32.55.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($2.25) earnings per share for the quarter, beating the consensus estimate of ($19.04) by $16.79. On average, analysts forecast that Cadrenal Therapeutics will post -6.72 EPS for the current year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.